WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Inc Stock Ownership - Who owns Halozyme Therapeutics?

Insider buying vs selling

Have Halozyme Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-10-1610,000$19.98
$199.80kBuy
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-10-1610,000$53.26
$532.59kSell
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-10-154,491$19.98
$89.73kBuy
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-10-159,923$53.74
$533.29kSell
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-10-1577$54.25
$4.18kSell
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-10-155,509$16.65
$91.72kBuy
Helen TorleyPRESIDENT AND CEO2024-10-0910,000$13.87
$138.70kBuy
Helen TorleyPRESIDENT AND CEO2024-10-091,615$53.31
$86.10kSell
Helen TorleyPRESIDENT AND CEO2024-10-092,404$53.91
$129.59kSell
Helen TorleyPRESIDENT AND CEO2024-10-095,981$51.85
$310.10kSell

1 of 12

HALO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when HALO insiders and whales buy or sell their stock.

HALO Shareholders

What type of owners hold Halozyme Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Randal J. Kirk20.93%26,633,924$1.35BInsider
Blackrock Inc13.85%17,619,937$891.04MInstitution
Vanguard Group Inc10.12%12,881,459$651.42MInstitution
State Street Corp4.57%5,814,207$294.02MInstitution
Snyder Capital Management L P3.18%4,039,912$204.30MInstitution
Artisan Partners Limited Partnership2.92%3,717,264$187.98MInstitution
Gregory Ian Frost2.86%3,641,380$184.14MInsider
Alliancebernstein LP2.79%3,549,075$179.48MInstitution
Macquarie Group Ltd2.42%3,077,527$155.63MInstitution
Jpmorgan Chase Co2.41%3,071,854$155.34MInstitution

1 of 3

HALO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
HALO77.95%22.05%Net SellingNet Selling
ASND100.00%0.00%
MDGL25.45%74.55%Net BuyingNet Selling
JAZZ27.40%72.60%Net SellingNet Selling
LEGN25.15%0.00%

Halozyme Therapeutics Stock Ownership FAQ

Who owns Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ: HALO) is owned by 96.01% institutional shareholders, 27.16% Halozyme Therapeutics insiders, and 0.00% retail investors. Randal J. Kirk is the largest individual Halozyme Therapeutics shareholder, owning 26.63M shares representing 20.93% of the company. Randal J. Kirk's Halozyme Therapeutics shares are currently valued at $1.52B.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.